Jay Motola

Icahn School of Medicine at Mount Sinai

Papers

3

Total Citations

136

H-Index

3

About

Dr. Jay Motola is a leading urologic surgeon and researcher whose work has fundamentally advanced the treatment of benign prostatic hyperplasia (BPH), particularly for patients with large prostate glands. His primary research focus is the development and validation of Aquablation therapy, a minimally invasive, robotically guided waterjet procedure. Dr. Motola’s major contribution is providing the highest level of evidence for this novel technology. As lead author of the landmark WATER II clinical trial, he has published the pivotal 1-year, 2-year, and final 5-year results, which collectively demonstrate Aquablation’s durable safety and efficacy in prostates 80-150 cc—a population historically challenging to treat. These works, accumulating over 130 citations, have established Aquablation as a standard of care, offering patients a less invasive alternative with lower rates of sexual dysfunction compared to traditional surgery. Dr. Motola’s rigorous, long-term data have been instrumental in reshaping clinical guidelines and expanding treatment options for men with symptomatic BPH, solidifying his reputation as a pioneer in modern urologic surgery.

Research Focus

Key Achievements

3
H-Index
3
Papers
136
Total Citations
45
Avg Citations/Paper
🏆 Most Cited Paper
Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results
63 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 29
🏛 Institutions: Icahn School of Medicine at Mount Sinai

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago